Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.58 |
| ▸ | SLC40A1 | Q9NP59 | 7/20 | 0.57 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561152 | 0.96 | MMP2 (0.59) | MMP2GAAMEN1KMT2AKCNA5 | |
| SCHEMBL5072751 | 0.87 | MEN1 (0.71) | MMP2GAAMEN1KMT2AKCNA5 | |
| SCHEMBL3562540 | 0.87 | SLC16A3 (0.73) | MMP2GAAMEN1KMT2AKCNA5 | |
| SCHEMBL3561833 | 0.83 | SLC16A3 (0.74) | MEN1KMT2AKCNA5SLC16A3ALDH1A1 | |
| SCHEMBL3558973 | 0.80 | SLC16A3 (0.69) | MEN1KMT2AKCNA5SLC16A3ALDH1A1 | |
| SCHEMBL5074828 | 0.79 | MEN1 (0.70) | MMP2GAAMEN1KMT2AKCNA5 | |
| SCHEMBL7388562 | 0.79 | MEN1 (0.70) | MMP2GAAMEN1KMT2AKCNA5 | |
| SCHEMBL3553446 | 0.79 | SLC16A3 (0.68) | MEN1KMT2AKCNA5SLC16A3ALDH1A1 | |
| SCHEMBL3558537 | 0.78 | TSHR (0.56) | MEN1KMT2ASLC16A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3552944 | 0.78 | SLC16A3 (0.56) | MMP2MEN1KMT2ASLC16A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | MMP2 1720/4885GAA 1191/4885MEN1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.